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Maintenance	of	skeletal	and	cardiac	muscle	structure	and	function	requires	precise	control	of	the	synthesis,	
assembly,	and	turnover	of	contractile	proteins	of	the	sarcomere.	Abnormalities	in	accumulation	of	sarcomere	
proteins	are	responsible	for	a	variety	of	myopathies.	However,	the	mechanisms	that	mediate	turnover	of	
these	long-lived	proteins	remain	poorly	defined.	We	show	that	muscle	RING	finger	1	(MuRF1)	and	MuRF3	
act	as	E3	ubiquitin	ligases	that	cooperate	with	the	E2	ubiquitin–conjugating	enzymes	UbcH5a,	-b,	and	-c	to	
mediate	the	degradation	of	β/slow	myosin	heavy	chain	(β/slow	MHC)	and	MHCIIa	via	the	ubiquitin	protea-
some	system	(UPS)	in	vivo and	in	vitro.	Accordingly,	mice	deficient	for	MuRF1	and	MuRF3	develop	a	skeletal	
muscle	myopathy	and	hypertrophic	cardiomyopathy	characterized	by	subsarcolemmal	MHC	accumulation,	
myofiber	fragmentation,	and	diminished	muscle	performance.	These	findings	identify	MuRF1	and	MuRF3	
as	key	E3	ubiquitin	ligases	for	the	UPS-dependent	turnover	of	sarcomeric	proteins	and	reveal	a	potential	basis	
for	myosin	storage	myopathies.
Introduction
Maintenance of striated muscle structure and function requires 
precise control of protein synthesis, processing, and degradation; 
abnormalities in these processes can give rise to myopathies (1). 
The ubiquitin proteasome system (UPS) is largely responsible for 
the degradation of misfolded proteins as well as long-lived proteins 
such as components of the contractile apparatus of striated muscles 
(2). Although activation of the UPS in skeletal muscle and heart has 
been primarily linked to a reduction in muscle mass as occurs dur-
ing muscle atrophy (3, 4), recent evidence has also shown the UPS to 
be activated during cardiac hypertrophy (5). Little is known of the 
molecular basis of these apparently opposing functions of the UPS.
Substrate specificity of the UPS is mediated by 3 groups of E3 
ubiquitin ligases, called RING finger, homologous to E6AP car-
boxyl terminus domain (HECT domain), and Skp1–Cul1–F-box 
protein complex (SCF complex) (6). Muscle RING finger (MuRF) 
proteins 1, 2, and 3 comprise a subfamily of the RING-finger 
E3 ubiquitin ligases that are expressed specifically in skeletal 
muscle and the heart (7). MuRF1 is upregulated during skeletal 
muscle atrophy, and mice lacking MuRF1 are resistant to atro-
phy (8). MuRF1 has also been implicated in cardiac hypertrophy 
(9). MuRF3 associates with microtubules and participates in the 
formation of cellular microtubular networks (7). Recently we 
reported that MuRF3 is involved in maintaining cardiac function 
and the integrity of the ventricular wall following acute myocar-
dial infarction (10). Given the similarity in structure and expres-
sion of MuRF proteins, it is likely that the phenotypes of mutant 
mice lacking individual MuRF proteins may reveal only a subset 
of MuRF functions due to redundancy.
The specific interaction partners of MuRF proteins and the 
consequences of such interactions are only beginning to be 
determined. MuRF proteins have been shown to localize to the 
sarcomere (7, 11, 12) and are capable of forming heterodimers 
(11). MuRF1 associates with titin at the M-band of the sarco-
mere, which has been proposed to maintain stability of the 
sarcomeric M-line region (13, 14). MuRF1 was also reported to 
function as an E3 ubiquitin ligase that catalyzes the ubiquitina-
tion of troponin I (15) and creatine kinase (16). MuRF1 and 
MuRF2, but not MuRF3, interact with titin, nebulin, troponin 
T, myotilin, myosin light chain 2, and T-cap, whereas MuRF1, 
MuRF2, and MuRF3 interact with troponin I (17). Recently we 
showed that MuRF3 interacts with and mediates degradation of 
γ-filamin and four-and-a-half LIM domain 2 (10). It remains to 
be determined whether all of these MuRF interacting proteins 
serve as substrates for ubiquitination and UPS-dependent deg-
radation or as scaffolding proteins.
Here we show that MuRF1–/–MuRF3–/– double mutant (DKO) mice 
display a distinct skeletal muscle and cardiac myopathy reminiscent 
of myosin storage myopathy (MSM) in humans. Skeletal and car-
diac muscles of DKO mice display a striking subsarcolemmal accu-
mulation of myosin heavy chain (MHC) accompanied by reduced 
maximal force development, cardiac hypertrophy, and decreased 
cardiac function. We demonstrate that MuRF1 and MuRF3 interact 
specifically with β/slow MHC and MHCIIa and utilize UbcH5a, -b, 
and -c as E2 ubiquitin–conjugating enzymes to catalyze the ubiqui-
tination and degradation of these contractile proteins. We conclude 
that MuRF1 and MuRF3 play a central role in the maintenance of 
skeletal muscle and cardiac structure and function, at least in part, 
by regulating MHC ubiquitination and degradation.
Nonstandard	abbreviations	used: ANF, atrial natriuretic factor; DKO,  
MuRF1–/–MuRF3–/–; MHC, myosin heavy chain; MSM, myosin storage  
myopathy; MuRF, muscle RING finger; PTU, propylthiouracil; UPS,  
ubiquitin proteasome system.
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Results
DKO mice display a skeletal muscle myopathy. To determine the roles 
of MuRF1 and MuRF3 in vivo and to identify possible redundant 
targets of these putative E3 ubiquitin ligases, we generated DKO 
mice. Although no obvious phenotype was detected in MuRF1–/– 
(8, 9) or MuRF3–/– (10) mice, DKO mice were less mobile and dis-
played a myopathic gait, difficulty walking and climbing, and a 
reduced step length compared with WT and single mutant litter-
mates (data not shown). This phenotype, affecting both male and 
female mice, included a significant decrease in body weight and 
size (Figure 1A) that was exacerbated with age (Figure 1F) and was 
accompanied by increased skeletal muscle mass (Figure 1E).
Histological analysis showed a myopathic phenotype in soleus, 
tibialis anterior (Figure 1B and Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI32827DS1), extensor digitorum longus (Supplemental Figure 1), 
gastrocnemius-plantaris muscles, and diaphragm (data not shown) 
of DKO animals. Strikingly, the myopathy was characterized by the 
Figure 1
DKO mice show a skeletal muscle myopathy. (A) Mice at 12 weeks of age. (B) H&E stain and (C) myosin ATPase activity of cross-sections from 
soleus and longitudinal sections from tibialis anterior muscles from 12-week-old WT and DKO mice. Subsarcolemmal eosinophilic material accu-
mulated along the entire length of the myofiber around a central myofiber core of DKO muscle. Heterogeneity of fiber size, atrophic myofibers 
(arrowhead), and centrally localized nuclei (long arrow) were found in DKO muscle. Solid lines indicate outer myofiber membrane. Dotted lines 
define the central core, which is surrounded by accumulated material (asterisk). Short arrow indicates basophilic boundary surrounding inner 
fiber. Quantitation of myofiber cross-sectional area and determination of occupied surface area of myofibers from soleus muscle (n = 6 each). 
(D) Measurement of force development and fatigability. Representative recordings of force from soleus muscles. Quantitation of maximum force 
development from soleus and extensor digitorum longus (n = 6 each). mN, millinewtons. (E) Quantitation of skeletal muscle mass (n = 12 each) 
of 12-week-old mice. (F) Measurement of body weight with increasing age. Scale bars: 20 μm. #P < 0.01 versus WT and MuRF1–/–; *P < 0.01 
versus MuRF3–/–; **P < 0.01 versus WT.
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subsarcolemmal accumulation of protein along the entire length 
of the myofiber surrounding a central myofiber core. In addition, 
myofibers from DKO animals showed an abnormal variability in 
fiber size as well as atrophic and split myofibers, an increase in the 
number of nuclei per myofiber, and centralized nuclei indicative 
of regeneration (Figure 1B and Supplemental Figure 1). Fiber type 
analysis of DKO skeletal muscle using a metachromatic dye ATPase 
assay (18) revealed intense metachromatic staining around the 
perimeter and along the entire longitudinal lengths of DKO myo-
fibers and showed no fiber type preference within the myopathic 
skeletal muscle (Figure 1C and Supplemental Figure 2). When 
soleus and extensor digitorum longus muscles were isolated and 
Figure 2
DKO mice display MSM. (A) Immunohistochemistry of soleus muscle using anti-laminin and anti-dystrophin antibodies. Dystrophin immunostaining 
was observed within myofibers only in DKO muscle. (B) Immunohistochemistry of soleus muscle using anti–β/slow MHC (red) and anti–pan-
MHCII (green) antibodies. Inset shows a representative myofiber with subsarcolemmal β/slow MHC accumulation (arrows). (C) Immunoblotting 
of proteins from the soluble (left blot) and particulate (right blot) fractions of the soleus revealed an accumulation of β/slow MHC in DKO muscle. 
Anti-GAPDH was used as a control. (D) Electron microscopy of longitudinal (top left and bottom) and cross (top right and middle) sections of 
soleus muscle displayed accumulation of granular material and unassociated myosins in DKO myofibers. Arrows indicate mitochondria. Dotted 
lines indicate separation of inner myofiber core (below the line) from accumulating myosin (above the line). Middle panel shows an enlargement 
of the area within the box at top right. Arrowheads point toward abnormal Z-lines. Bottom: Z-line streaming found in skeletal muscle myopathies 
is seen in the top of this panel. M, M-line; N, nucleus. (E) NADH stain of soleus and tibialis anterior muscles shows disorganized mitochondria in 
DKO muscle. (F) Modified Gomori trichrome stain of soleus and tibialis anterior muscles shows no ragged red fiber myopathy. Scale bars: 100 μm 
(A and B); 2 μm (D, top left and bottom); 0.5 μm (D, top right and middle); 20 μm (E and F).
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subjected to continuous electrical stimulation to measure muscle 
performance, we observed a profound reduction in maximum force 
in DKO mice compared with MuRF1–/–, MuRF3–/–, and WT litter-
mates, with no significant changes in fatigability (Figure 1D).
H&E staining of skeletal muscle from DKO mice revealed a 
basophilic demarcation separating the central myofiber core 
from the surrounding accumulating material (Figure 1B). 
Immunohistochemistry using anti-laminin and anti-dystrophin 
antibodies (Figure 2A) and electron microscopy (Figure 2D) 
showed no evidence of a limiting membrane separating the central 
myofiber core from the accumulating material, indicating that the 
accumulating material was contained within the DKO myofiber 
rather than an adjacent cell. Interestingly, some individual myo-
fibers of the DKO soleus muscle were immunoreactive for dystro-
phin (Figure 2A), a condition reported as a general characteristic 
of human skeletal muscle myopathies (19).
Figure 3
DKO mice exhibit hypertrophic cardiomyopathy and decreased cardiac function. (A) H&E stain of hearts. Solid and dotted lines indicate outer 
myofiber and inner core diameter, respectively. (B) Heart weight/body weight ratios showed cardiac hypertrophy in DKO mice. (C) Echocar-
diography revealed decreased LV systolic function (fractional shortening), increased LV end-systolic diameter (LVESD), and an unchanged LV 
end-diastolic diameter (LVEDD). (D) Electron microscopy of heart showed accumulated and disoriented thick filaments and displacement of 
mitochondria (arrow). Solid and dotted lines indicate outer myofiber and inner core diameter, respectively. Bottom panel is magnification the 
box in the top right panel, showing ultrastructure of accumulated myosin filaments in the cardiomyocyte. (E) Immunoblotting of proteins from 
hearts revealed accumulation of undegraded (cytosolic fraction; top 3 panels) and degraded (pellet fraction; bottom 2 panels) β/slow MHC in 
DKO muscle. α-MHC expression remained unchanged. (F) Expression of hypertrophic markers ANF and β/slow MHC as assessed by real-time 
PCR analysis. α-MHC expression remained unchanged. #P < 0.01 versus WT and MuRF1–/–; *P < 0.01 versus MuRF3–/–. Scale bars: 1 mm (A, 
top); 20 μm (A, bottom); 2 μm (D).
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Abnormal accumulation of myosins in DKO myofibers. Analysis of 
proteins isolated from soleus of WT, MuRF1–/–, MuRF3–/–, and 
DKO mice by SDS-PAGE revealed a band of approximately 60 kDa 
that was specific to DKO muscle (data not shown). Mass spec-
trometry identified this band as fragments of myosin proteins, 
which normally migrate at about 200 kDa (Supplemental Table 1). 
Immunohistochemistry of DKO soleus muscle using anti–β/slow 
MHC and anti–pan-MHCII antibodies confirmed the accumula-
tion of both proteins within their respective myofibers (Figure 2B). 
MHC proteins accumulated as an amorphous homogenous mass 
surrounding a central myofiber core (Figure 2B). Immunoblot anal-
ysis of isolated protein from WT and DKO skeletal muscle showed 
a massive accumulation of undegraded and degraded β/slow MHC 
in DKO soleus (Figure 2C) and revealed that the increase in MHCII 
protein was mainly MHCIIa (Figure 2C) in DKO soleus.
Electron microscopy performed on sections of soleus showed 
protein aggregates only in DKO myofibers, leading to a redistribu-
tion of mitochondria along the centralized myofiber (Figure 2D). 
This was confirmed by NADH staining (Figure 2E and Supple-
mental Figure 3).
As observed in MSM (20, 21), we found that the DKO myofibers 
were degraded into granular material that accumulated around a cen-
tral myofiber core (Figure 2D). The amorphous material contained 
unassociated filaments and fragments of sarcomeres. Measurements 
of the filaments in cross and transverse sections showed the filament 
thickness to be 15 nm, consistent with that of myosin filaments (22), 
validating the identity of the granular material as MHC protein (data 
not shown). Disoriented sarcomeres seen in cross and longitudinal 
sections of mutant DKO skeletal muscle had an intact M-line struc-
ture with adjacent thick filaments, suggesting a role of MuRF1 and 
MuRF3 in the turnover of thick filaments and M-line proteins. In 
contrast, the Z-line was greatly diminished or absent (Figure 2D), 
suggesting that mechanisms independent of MuRF1 and MuRF3 
mediate degradation of Z-line proteins. In addition, disorganized 
and non-aligned, blurred, broadened, and disrupted Z-lines, known 
as Z-line streaming, a general feature of many myopathic disorders, was 
observed in skeletal muscle of DKO mice (Figure 2D).
To determine whether the myopathy seen in DKO muscle 
resembled nemaline myopathy, another striated muscle disorder, 
Gomori trichrome staining was performed. The results showed no 
evidence of ragged-red fibers, a hallmark of nemaline body myopa-
thy (23) (Figure 2F and Supplemental Figure 4).
DKO mice exhibit hypertrophic cardiomyopathy. Hearts of DKO mice 
were hypertrophic, indicative of cardiac stress (Figure 3, A and B). 
Echocardiography showed a pronounced reduction of LV systolic 
function due primarily to an enlargement of the LV end-systolic 
dimension, whereas the LV end-diastolic dimension remained 
unchanged (Figure 3C). As in skeletal muscle, cardiomyocytes of 
DKO animals contained a sharply demarcated accumulation of 
subsarcolemmal protein composed of granular material and unas-
sociated myosins. Mitochondria were redistributed along the cen-
tralized myofiber core (Figure 3, A and D). Immunoblotting showed 
an accumulation of β/slow MHC protein and its breakdown prod-
ucts in hearts of DKO compared with MuRF1–/–, MuRF3–/–, or WT 
littermates (Figure 3E). In contrast, expression of α-MHC, the adult 
cardiac myosin isoform, was not changed (Figure 3E). Atrial natri-
uretic factor (ANF), a marker of cardiac stress, was upregulated in 
DKO hearts compared with littermate controls (Figure 3F).
MuRF1 and MuRF3 interact with and ubiquitinate MHC proteins in vitro. 
To begin to define the mechanistic basis of MHC accumulation 
in DKO muscles, we tested whether MuRF1 and MuRF3 interact 
with β/slow MHC and MHCIIa proteins. Indeed, the interaction of 
MuRF1 and MuRF3 proteins with the N-terminal regions of β/slow 
MHC and MHCIIa was readily apparent by coimmunoprecipita-
tion assays using transfected COS-7 cells in vitro (Figure 4A). Bind-
ing was mediated by the S1 and S2 subfragments of myosin, which 
contain the globular head domain, responsible for ATP-dependent 
cross-bridge formation between thick and thin filaments, and a 
long α-helix domain, which is important for myosin dimerization. 
We used recombinant proteins encoding the N-terminal MuRF-
interacting regions of β/slow MHC and MHCIIa protein for sub-
sequent in vitro ubiquitination assays. We found that both MuRF1 
and MuRF3 ubiquitinate residues within the N terminus of β/slow 
MHC (Figure 4B) as well as MHCIIa (Supplemental Figure 5A). 
We then systematically tested a series of E2 ubiquitin–conjugating 
enzymes for their ability to cooperate with MuRF1 and MuRF3 to 
ubiquitinate β/slow MHC and MHCIIa and found that MuRF1 and 
MuRF3 use the E2 ubiquitin–conjugating enzymes UbcH5a, -b, 
and -c and, to a lesser degree, UbcH2 to execute this reaction 
(Figure 4B and Supplemental Figure 5A). No differences in ubiqui-
tination efficiency between these E2 ubiquitin–conjugating enzymes 
and MuRF1 and MuRF3 were observed, indicating that both 
MuRF proteins use the same E2 ubiquitin–conjugating enzymes 
for the ubiquitination of β/slow MHC and MHCIIa. In contrast, 
the E2 ubiquitin–conjugating enzymes UbcH3, -6, -7, and -10 did 
not facilitate ubiquitination by MuRF1 and MuRF3 (Figure 4B 
and Supplemental Figure 5A). RING-finger deletion mutants of 
MuRF1 and MuRF3 were unable to ubiquitinate β/slow MHC or 
MHCIIa regardless of the E2 ubiquitin–conjugating enzyme used 
(Figure 4C and Supplemental Figure 5B). In control experiments, 
no unspecific ubiquitination signal was detected, indicating speci-
ficity of the in vitro ubiquitination assays (Figure 4D).
MuRF1 and MuRF3 mediate β/slow MHC ubiquitination and turn-
over in vivo. β/Slow MHC is upregulated in the heart in response 
to hypothyroidism. To further examine the ability of MuRF1 and 
MuRF3 to mediate the ubiquitin-dependent turnover of β/slow 
MHC in vivo, we induced the expression of β/slow MHC in the 
heart by administering propylthiouracil (PTU), an inhibitor of 
T3 biosynthesis (24), to MuRF1–/–, MuRF3–/–, and WT mice for 2 
weeks (Figure 5A). We used only the single MuRF mutant mice to 
induce β/slow MHC in the heart with PTU because the amount of 
β/slow MHC in the single MuRF mutant mouse is similar to that 
in WT mice (Figure 5A) and because DKO mice had a high base-
line content of β/slow MHC in the heart (Figure 3E). Hypothy-
roidism led to a comparable increase in β/slow MHC (Figure 5A) 
and a decrease in α-MHC mRNA (Figure 5B) in the hearts of WT, 
MuRF1–/–, and MuRF3–/– mice. After withdrawal of PTU for 2 sub-
sequent weeks, we compared the amount of β/slow MHC protein 
present as a readout for β/slow MHC degradation in the heart. 
Although β/slow MHC mRNA decreased in WT, MuRF1–/–, and 
MuRF3–/– hearts to similar levels, the content of β/slow MHC pro-
tein was elevated in the hearts of MuRF1–/– and MuRF3–/– mutant 
mice compared with WT littermates (Figure 5C). This finding sug-
gests that the absence of either MuRF1 or 3 leads to a reduction of 
β/slow MHC degradation in the heart in vivo.
MuRF1 and MuRF3 mediate increased myosin degradation in vitro.	To 
further examine the ability of MuRF1 and MuRF3 to promote myo-
sin degradation, we overexpressed MuRF1 or MuRF3 in C2C12 myo-
blasts and analyzed MHC protein expression during myotube dif-
ferentiation, which occurs when MHC proteins accumulate (25). We 
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Figure 4
MuRF1 and MuRF3 interact 
with and ubiquitinate β/slow 
MHC in vitro. (A) Schematic 
diagram of interaction mapping 
between MuRF1 and MuRF3 
and β/slow MHC shows that 
MuRF1 and MuRF3 interact 
with multiple domains of β/
slow MHC. S1, subfragment 1; 
LMM, light meromyosin. (B) 
In vitro ubiquitination assays 
were performed with recom-
binant E1 ubiquitin–activating 
enzymes, E2 ubiquitin–conju-
gating enzymes, MBP-MuRF1 
or MBP-MuRF3, ubiquitin, and 
GST–β/slow MHC. (B, C, and 
D) Ubiquitin protein conjugates 
were resolved by SDS-PAGE 
and detected by anti-ubiquitin 
antibody. Ubiquitination activ-
ity as assessed by the detec-
tion of high molecular weight 
multiubiquitin chains. (C) In 
vitro ubiquitination assays 
were performed with recombi-
nant E1; UbcH5a, -5b, and -5c; 
ubiquitin; GST–β/slow MHC; 
MBP-MuRF1 and MBP-MuRF3; 
and RING-finger delet ion 
mutants MBP-MuRF1ΔRF and 
MBP-MuRF3ΔRF. Ubiquitina-
tion activity of MuRF1 and 
MuRF3 toward GST–β/slow 
MHC was abolished when the 
RING-finger domains of MuRF1 
and MuRF3 were deleted. (D) 
In vitro ubiquitination assays 
were performed with different 
combinations of recombinant 
E1, UbcH5c, ubiquitin, GST–β/
slow MHC, and MBP-MuRF3. 
No ubiquitin protein conjugates 
were detected when GST or 
MBP proteins (2 far right lanes 
of panel) were used instead of 
GST–β/slow MHC, confirming 
the specificity of the assay.
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observed less accumulation of MHC in differentiating C2C12 myo-
tubes in the presence of MuRF1 or MuRF3, suggesting that MuRF1 
and MuRF3 inhibit accumulation of MHC in skeletal muscle cells 
(Figure 5D), whereas myogenin expression was similar in control cells 
and cells expressing MuRF protein, indicating that MuRF expression 
did not block myotube differentiation (Figure 5D).
Discussion
The results of this study show that MuRF1 and MuRF3 function 
redundantly to control the ubiquitin-dependent degradation of β/
slow MHC and MHCIIa proteins in striated muscles. The deletion 
of both MuRF1 and MuRF3 in mice causes the abnormal accumu-
lation of MHC thick filaments and ultrastructural abnormalities 
in skeletal and cardiac muscles, resulting in a severe decrease in 
muscle function. This phenotype 
and its consequences are remi-
niscent of the human myopathy 
MSM as well as hypertrophic car-
diomyopathy, both of which have 
been linked to mutations within 
the MYH7 gene, which encodes β/
slow MHC protein (26–33). How-
ever, in contrast to the human 
MSM, which is restricted to type I 
myofibers, we did not find a fiber 
type–restricted phenotype within 
DKO skeletal muscle. This differ-
ence from classical MSM, which 
is caused by a mutation the MYH7 
gene encoding β/slow MHC (which 
is restricted to the heart and type I 
myofibers), reflects the lack of fiber 
type specificity of expression of 
MuRF1 and MuRF3 as well as their 
apparent ability to ubiquitinate 
MHCIIa and β/slow MHC. Thus a 
fiber type–restricted phenotype in 
DKO mice would not be expected. 
In addition, not all patients with 
MSM display a myopathy of both 
the skeletal muscle and the heart 
(26–33), whereas both muscles 
were affected in our DKO mice. 
Despite these differences we believe 
that the accumulation of myosin 
and the reduced performance of 
the affected muscle justifies the 
description of the phenotype of 
the DKO mouse as a MSM.
The mechanisms that medi-
ate degradation of sarcomeric 
proteins have been the focus of 
intense interest (34). Loss of mus-
cle proteins during cachexia (35), 
diabetes (36), sepsis (37), and neu-
rological disorders (38) is thought 
to be mediated primarily by activa-
tion of the UPS. Although myosin 
proteins have been shown to be 
ubiquitinated (39), no specific 
E3 ubiquitin ligase or accompanying E2 ubiquitin–conjugating 
enzymes that mediate UPS-dependent MHC degradation have been 
identified. Moreover, although several interaction partners have 
been identified for MuRF3 (10), no E3 ubiquitin ligase activity has 
been demonstrated for MuRF3 to date. Here we show that β/slow 
MHC and MHCIIa serve as overlapping targets for ubiquitination 
and UPS-dependent degradation by MuRF1 and MuRF3 together 
with the E2 ubiquitin–conjugating enzymes UbcH5a, -b and -c.
Because MuRF proteins display both E3 ubiquitin ligase activity 
and play roles in stabilizing sarcomere structure and microtubules 
(7, 10, 11, 40), the phenotype of DKO mice might reflect not only the 
loss of ubiquitin ligase activity but also a loss of structural integrity 
of striated muscle cells. However, the accumulation of myosin in the 
absence of MuRF1 and MuRF3 and our data showing that MuRF1 
Figure 5
MuRF1 and MuRF3 mediate MHC protein turnover in vivo. (A and B) PTU was administered for 2 weeks 
to induce expression of β/slow MHC in WT, MuRF1–/–, and MuRF3–/– mouse hearts (n = 6 each). Expres-
sion of β/slow MHC (A) and α-MHC (B) mRNA as assessed by real-time PCR analysis was increased 
and decreased, respectively, to comparable levels after 2 weeks of PTU treatment in all genotypes. 
Terminating the administration of PTU treatment led to a normalization of β/slow MHC and α-MHC 
mRNA expression. (C) Immunoblotting of proteins from hearts of WT, MuRF1–/–, and MuRF3–/– mice 
showed a reduced degradation of β/slow MHC in MuRF1–/– and MuRF3–/– compared with WT mice. Anti-
tubulin antibody was used as a control. (D) Immunoblots of lysates from C2C12 myoblasts (MB) and 
differentiating myotubes (MT; days of differentiation are indicated at top) transfected with MuRF1-myc 
or MuRF3-myc, using anti-MHC antibody show a reduced MHC content when MuRF1 or MuRF3 were 
coexpressed. Transfection of pcDNA3.1 was used as a control. Anti-myogenin, was used as a control for 
differentiation, and anti-myc and anti-tubulin antibodies were used as controls for input.
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and MuRF3 mediate ubiquitination and degradation of myosin 
strongly argue that the loss of MuRF1 and MuRF3 ubiquitin ligase 
activity contributes significantly to the phenotype of DKO mice.
Interestingly, although we found that MHC proteins are direct 
targets of MuRF1 and MuRF3, the absence of both E3 ubiquitin 
ligases did not affect the entire myofiber, as an apparently intact 
inner myofiber core was still present and surrounded by accumu-
lating MHC proteins in DKO muscle. Thus it is tempting to spec-
ulate that MuRF1 and MuRF3 preferentially affect degradation 
of the soluble cytosolic fraction of MHC proteins rather than the 
MHC fraction that is associated with the sarcomere, which may 
actually be stabilized by MuRF proteins.
Because MuRF1 and MuRF3 promote the degradation of MHC 
proteins, we expected that loss of MuRF1 and MuRF3 would lead 
to accumulation of undegraded MHC. However, we observed an 
accumulation of both undegraded and degraded MHC in DKO 
muscle. This suggests that other MHC-degrading mechanisms, 
most likely non–proteasome dependent, may be activated in DKO 
muscle but are clearly not sufficient for complete MHC degrada-
tion. Several proteinases such as trypsin-like serine proteinase (41), 
calpain (42), cathepsin B/L (43, 44), and chymase (44) are activated 
during muscular dystrophy. In particular, trypsin-like serine pro-
teinase mediates myosin cleavage (41) with myosin breakdown 
products similar to those we observed in DKO soleus (Figure 2C). 
Furthermore, treatment of myofibrils with a thiol proteinase result-
ed in the loss of the Z-disc (41), a finding analogous to our electron 
microscopy findings in which virtually no Z-disc structures were 
found within the accumulating MHC of DKO muscle. We therefore 
conclude that MuRF1 and MuRF3 are the key enzymes for UPS-
dependent MHC degradation in striated muscle. This observation 
is important because the degradation of actomyosin complexes by 
the UPS is reduced compared with uncomplexed myosin and actin 
molecules (39) and the access of the sarcomere by the UPS is par-
tially mediated by proteases such as caspase-3 (45) and calpain-1 
(46), which are known to augment ubiquitination of structural 
proteins. It is therefore possible that activation of these proteases 
could be important for the initiation of myosin turnover in the 
myopathic DKO muscle and worsen the phenotype by producing 
substrates for UPS-dependent degradation. However, since MuRF1 
and MuRF3 appear to be the rate-limiting enzymes regulating myo-
sin ubiquitination and degradation, we believe that their absence is 
the primary cause of the DKO phenotype.
β/slow MHC is downregulated in the adult mouse heart but can 
be reversibly upregulated by pharmacological induction of hypo-
thyroidism, providing a means of monitoring β/slow MHC degra-
dation in the presence or absence of MuRF1 and MuRF3 proteins in 
vivo. We found that β/slow MHC degradation was greatly reduced 
in MuRF1 and MuRF3 single mutant mice compared with WT 
mice, further supporting a role of MuRF1 and MuRF3 in β/slow 
MHC degradation in the heart. Conversely, overexpression of 
MuRF1 and MuRF3 protein inhibited accumulation of MHC pro-
tein in differentiating C2C12 cells, indicating that MHC proteins 
are indeed targets for MuRF1- and MuRF3-dependent degradation. 
Interestingly, MuRF3 expression (7) parallels that of MHC (25) dur-
ing C2C12 cell differentiation, which might reflect a mechanism by 
which myosin turnover is regulated during differentiation.
Nemaline myopathy, although clinically similar to myosin stor-
age myopathies, is caused by mutations in a variety of genes encod-
ing sarcomeric thin filament proteins, including nebulin (47), 
α-actin 1 (48), and troponin T1 (49). Although MuRF proteins 
have been shown to interact with nebulin and troponin T (17), our 
results using modified Gomori trichrome stain indicated that the 
phenotype observed in DKO muscle is mainly related to perturbed 
degradation and accumulation of myosin-thick but not -thin fila-
ments. The accumulating MHC in DKO skeletal muscle caused a 
displacement of mitochondria, which likely resulted in inefficient 
energy supply to the contractile apparatus, thereby augmenting 
the phenotype in DKO muscle.
The cardiac phenotype observed in DKO mice consists of an 
increased heart weight, decreased cardiac function, and increased 
ANF expression. This phenotype is indicative of a hypertrophic car-
diomyopathy and is likely to be caused by the accumulation of β/slow 
MHC protein in cardiomyocytes. Although we favor the hypothesis 
that the increase in β/slow MHC protein is mainly due to a lack of 
MuRF1- and MuRF3-dependent degradation, we are aware that β/
slow MHC protein expression is also upregulated in response to car-
diac stress. It is possible that the cardiac hypertrophy in DKO mice 
contributes to the accumulation of β/slow MHC observed in DKO 
hearts, further exacerbating the cardiac phenotype of DKO mice.
Muscular atrophy accompanies various clinically important dis-
eases and determines the quality of life and mortality of patients. 
The development of novel therapeutic strategies to treat this 
disease requires a detailed understanding of the specific mecha-
nisms that lead to the degradation of sarcomeric proteins. Indeed, 
MuRF1 plays a role in muscular atrophy (8), and it was proposed 
that MuRF inhibitors could be beneficial to treat skeletal muscle 
atrophy. However, based on our findings presented here and pub-
lished earlier (10), administration of nonspecific MuRF inhibitors 
seems likely to cause adverse side effects, especially due to myosin 
accumulation in striated muscle cells. To be therapeutically effec-
tive, we propose that MuRF inhibitors should be designed to be 
isoform specific and to specifically disrupt the interaction between 
MuRF proteins and their targets.
Methods
Animal studies. MuRF1 (8) and MuRF3 (10) mutant mice have been pre-
viously described. Animals were housed under standard conditions and 
maintained on commercial mouse chow and water ad libitum unless 
otherwise indicated. The environment was maintained at 22°C with a 
12-hour light/12-hour dark cycle. MuRF1 and MuRF3 double heterozygous 
mutant mice were interbred, and resulting WT, MuRF1–/–, MuRF3–/–, and 
DKO littermates of the same gender were used for subsequent experiments. 
All animal experimental procedures were reviewed and approved by the 
Institutional Animal Care and Use Committees at the University of Texas 
Southwestern Medical Center.
Induction of hypothyroidism by administering PTU.	Hypothyroidism of 
8-week-old male WT, MuRF1–/–, and MuRF3–/– mice (n = 6 each) was induced 
by feeding PTU, a commonly used anti-thyroid drug (24). Animals were 
divided into 2 groups; group 1 was sacrificed after 2 weeks of PTU treat-
ment (n = 3 each), and the PTU diet for group 2 was changed to normal 
chow after 2 weeks of PTU treatment for an additional 2 weeks (n = 3 each). 
PTU-treated mice received 0.15% PTU feed (Harlan Teklad). WT, MuRF1–/–, 
and MuRF3–/– mice that received regular feed and drinking water for 4 
weeks served as controls (n = 3 each). Hearts were flash-frozen in liquid 
nitrogen and stored at –80°C for subsequent analysis.
Muscle fatigue measurements. Measurements of muscle fatigue were per-
formed as previously described (50). To compare muscle function of WT, 
MuRF1–/–, MuRF3–/–, and DKO mice, male and female littermates and mice 
of the same age were analyzed. The soleus and extensor digitorum longus 
muscles were isolated from anesthetized mice and immediately mounted 
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between a fixed clamp at the base of a water-jacketed organ bath and a 
Grass FTO3C isometric force transducer. Muscles were equilibrated for 15 
minutes in an oxygenated (95% O2 and 5% CO2) physiological salt solution 
containing 120.5 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO4, 1.5 mM CaCl2, 
1.2 mM Na2PO4, 20.4 mM NaHCO3, 10 mM dextrose, and 1 mM pyruvate, 
at 30°C and pH 7.6. The muscles were adjusted to the optimal length fol-
lowed by 30 minutes of resting. Muscles were then stimulated at 100 Hz 
until the force output dropped to 10% of the initial level. The time taken to 
reach 10%, 30%, and 50% of the original force was measured and used as an 
indication of muscle fatigability. The force development in millinewtons 
was normalized to the muscle mass in milligrams.
Histology and electron microscopy analyses. Skeletal muscle and hearts were 
harvested, fixed with 3.7% paraformaldehyde, processed, and stained 
with H&E as previously described (10). Images were acquired with a Leica 
DM2000 microscope and an Optronics DEI-750 charge-coupled device 
digital camera and analyzed using ImageJ software 1.62c (http://rsb.info.
nih.gov/ij/) to calculate myofiber cross sectional area.
Electron microscopy was performed as previously described (10). Brief-
ly, soleus muscle and tissue of the interventricular septum of the heart of 
8-week-old male littermate WT, MuRF1–/–, MuRF3–/–, and DKO mice were 
dissected and fixed in 2% glutaraldehyde in 0.1 M cacodylate buffer over-
night at 4°C. The tissue was postfixed and stained with 1% osmium tetrox-
ide in 0.1 M cacodylate buffer, incubated with uranyl acetate, and dehy-
drated with ethanol. The tissues were subsequently rinsed with propylene 
oxide and embedded using EMBED 812. Longitudinal and thin cross-sec-
tions (60 nm) were counterstained with uranyl acetate and lead citrate and 
examined on a Jeol 1200 electron microscope. Photographs were taken at 
the magnifications indicated in the figure legends.
Immunohistochemical analysis and metachromatic assays of skeletal muscle. 
Soleus, tibialis anterior, extensor digitorum longus, and gastrocnemius-
plantaris muscles were harvested from WT, MuRF1–/–, MuRF3–/–, and DKO 
mice and either flash frozen in embedding medium containing a 3:1 mix-
ture of Tissue Freezing Medium (Triangle Biomedical Sciences) and gum 
tragacanth (Sigma-Aldrich) or fixed in 4% paraformaldehyde and processed 
for routine paraffin histology. Frozen sections were cut on a cryotome and 
stained histochemically for ATPase enzyme activity or modified Gomori 
trichrome as previously described (18, 21); β-nicotinamide adenine dinu-
cleotide reduced disodium salt hydrate and Gomori 1 Step Trichrome 
with Light Green were purchased from Sigma-Aldrich and Poly Scientific, 
respectively. Paraffin and frozen histological sections were stained immu-
nohistochemically for β/slow MHC (NOQ7, monoclonal; Sigma-Aldrich), 
pan-MHCII (My32, monoclonal; Sigma-Aldrich), laminin (polyclonal; 
Sigma-Aldrich), and dystrophin (monoclonal; Chemicon).
Cell culture, transfection, and coimmunoprecipitation. Cell culture experiments 
were performed using COS-7 and C2C12 cells maintained in Dulbecco’s 
modified Eagle’s medium supplemented with 10% fetal bovine serum, 2 mM 
l-glutamine, and penicillin/streptomycin and transfected using FuGENE 6 
Transfection Reagent (Roche Applied Science) and Lipofectamine and PLUS 
Reagent (Invitrogen) according to the manufacturer’s instructions, respec-
tively. Differentiation of C2C12 cells was induced 24 hours after transfec-
tion for time points indicated in Figure 5D using DMEM supplemented 
with 2% horse serum, 2 mM l-glutamine, and penicillin/streptomycin. All 
experiments were conducted in duplicate and repeated at least 3 times.
Expression plasmids containing aminoterminal FLAG- and Myc-tagged 
derivatives of MuRF3 were previously published (7, 10). Expression plasmids 
containing aminoterminal FLAG-tagged and carboxyterminal Myc-tagged 
derivatives of MuRF1 and MuRF3 and aminoterminal Myc-tagged deriva-
tives of β/slow MHC and MHCIIa were generated using HighFidelity Taq 
DNA polymerase using mouse cDNA as template. For recombinant pro-
teins, full-length and RING-finger–deleted (∆RF) MuRF1 and MuRF3 were 
subcloned into pMAL-c2x expression plasmids (NEB), and DNA fragments 
encoding amino acids 2–128 of WT β/slow MHC and amino acids 2–255 
WT MHCIIa were subcloned into the pGEX-4T1 vector.
For immunoprecipitation studies, cells were harvested in lysis buffer (50 
mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF) 
and supplemented with protease inhibitors (Complete; Roche Diagnostics), 
and FLAG- and myc-tagged proteins were immunoprecipitated with M2-
agarose conjugate (Sigma-Aldrich) and anti-myc antibody (polyclonal; Santa 
Cruz Biotechnology Inc.), respectively, as previously described (10). Bound 
proteins were resolved by SDS-PAGE, transferred to PVDF membranes, and 
immunoblotted using either anti-Myc (polyclonal, A-14; Santa Cruz Biotech-
nology Inc.) or anti-FLAG (monoclonal, M2; Sigma-Aldrich) antibody. Load-
ing controls were detected with anti–α-tubulin (monoclonal; Sigma-Aldrich) 
or anti-GAPDH antibody (monoclonal; Millipore). Proteins were visualized 
with a chemiluminescence system (Santa Cruz Biotechnology Inc.). Western 
blot analysis was also performed on protein samples from mouse hearts and 
skeletal muscles, as previously described (10, 51) using anti–β/slow MHC 
(NOQ7, monoclonal; Sigma-Aldrich), anti–pan-MHCII (My32, monoclonal; 
Sigma-Aldrich), or anti-MHCIIa antibody (sc-71 antibody was a gift from 
Zhen Yan, Duke University, Durham, North Carolina, USA). Silver staining 
of proteins from cardiac muscle was performed as previously described (50). 
Loading controls were detected with anti-GAPDH (monoclonal; Millipore) 
and anti-actin (monoclonal; Sigma-Aldrich) antibody.
In vitro ubiquitination assay and mass spectrometry. In vitro ubiquitination assays 
were performed as published (52). Briefly, 500 ng of MBP-MuRF1, MBP-
MuRF1∆RF, MBP-MuRF3, or MBP-MuRF3∆RF; 500 ng of GST–β/slow MHC 
or GST-MHCIIa; 0.3 μM purified E1 ubiquitin–activating enzyme (Boston 
Biochem); 40 mg/ml ubiquitin (Sigma-Aldrich); 8 mM ATP (Sigma-Aldrich); 
and 1 μM of E2 ubiquitin–conjugating enzyme as indicated	in Figure 4B 
(Boston Biochem) were incubated in 100 mM Tris-Cl, pH 7.6, 10 mM MgCl2, 
1 mM DTT, 50 μM MG132, and 2 mM NaVO4 protease inhibitors (Complete; 
Roche Diagnostics) for 2 hours at 30°C. Ubiquitin-protein conjugates were 
resolved by SDS-PAGE and detected by anti-ubiquitin antibody (polyclonal; 
Santa Cruz Biotechnology Inc.). Ubiquitination activity was assessed by the 
detection of high-molecular-weight multiubiquitin chains. Mass spectrom-
etry was performed as previously published (53).
Semiquantitative RT-PCR.	Total RNA was isolated from skeletal muscles 
and the left ventricle of mice using TRIzol Reagent (Invitrogen). Total 
RNA was DNAse digested, and cDNA synthesis of 1.5 μg of RNA was car-
ried out using a SuperScript First-Strand Synthesis System for RT-PCR 
(Invitrogen). Real-time PCR was performed using either SYBR Green (ABI) 
with primer sets and PCR conditions that have been previously published 
(50) or TaqMan Universal PCR Mastermix (Applied Biosystems) with com-
mercially available primer and probe sets as previously described (10, 51).
Statistics. Values are presented as mean ± SEM. Gene expression was nor-
malized to GAPDH mRNA and calculated as relative change. Differences 
in morphologic, physiologic, and biochemical parameters between groups 
were analyzed by Mann-Whitney U test or 2-sided Student’s t test. Statis-
tics were calculated with Microsoft Excel 2002 and SPSS 11.0 software. A 
P value of less than 0.05 was considered to be statistically significant.
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